A case-control study of the effectiveness of tissue plasminogen activator on 6 month patients--reported outcomes and health care utilization.
A case-control study of the effectiveness of tissue plasminogen activator on 6 month patients--reported outcomes and health care utilization.
复制标题
组织纤溶酶原激活剂对 6 个月患者有效性的病例对照研究——报告结果和医疗保健利用。
DOI：
10.1016/j.jstrokecerebrovasdis.2014.07.049
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Lee,Jin-Moo
中科院分区：
文献类型：
--
作者：
Lang,CatherineE;Bland,MarghurettaD;Cheng,Nuo;Corbetta,Maurizio;Lee,Jin-Moo
我们研究了组织型纤溶酶原激活剂(TPA)，作为常规卒中治疗的一部分，对患者报告的结果和医疗保健利用的益处。采用病例对照设计，将接受tPA作为常规卒中治疗的一部分的患者与如果他们在治疗时间窗口内到达医院就会接受tPA的患者进行比较。数据是从中风后6个月的调查中收集的，使用标准化的患者报告的结果衡量标准和有关医疗保健利用的问题。人口统计和医疗数据从医院记录中获得。患者在中风严重程度、年龄、种族和性别上进行匹配。TPA与对照组按1：2比例配对。由于有有利于tPA组的方向性特定假设，结果在使用单尾检验的组之间进行了比较。TPA组(n=78)和对照组(n=156)在所有变量上都是匹配的，除了中风严重程度，这在对照组中更好；随后的分析控制了这种不匹配。与对照组相比，tPA组的身体功能、沟通能力、认知能力、抑郁症状和生活/参与质量都有所改善。与对照组相比，tPA组报告的熟练护理设施停留、急诊科就诊和中风后再次住院的人数较少。其他急性后服务的报告在不同组之间没有不同。虽然已知tPA可减少残疾，但这是第一项证明tPA在改善有意义的、患者报告的结果方面的有效性的研究。因此，tPA的使用为缺血性中风患者的日常生活提供了很大的好处。
We examined the benefit of tissue plasminogen activator (tPA), delivered as part of usual stroke management, on patient-reported outcomes and health care utilization. Using a case control design, patients who received tPA as part of usual stroke management were compared with patients who would have received tPA had they arrived to the hospital within the therapeutic time window. Data were collected from surveys 6 months after stroke using standardized patient-reported outcome measures and questions about health care utilization. Demographic and medical data were acquired from hospital records. Patients were matched on stroke severity, age, race, and gender. Matching was done with 1:2 ratio of tPA to controls. Results were compared between groups with 1-tailed tests because of a directionally specific hypothesis in favor of the tPA group. The tPA (n = 78) and control (n = 156) groups were matched across variables, except for stroke severity, which was better in the control group; subsequent analyses controlled for this mismatch. The tPA group reported better physical function, communication, cognitive ability, depressive symptomatology, and quality of life/participation compared with the control group. Fewer people in the tPA group reported skilled nursing facility stays, emergency department visits, and rehospitalizations after their stroke compared with controls. Reports of other postacute services were not different between groups. Although it is known that tPA reduces disability, this is the first study to demonstrate the effectiveness of tPA in improving meaningful, patient-reported outcomes. Thus, use of tPA provides a large benefit to the daily lives of people with ischemic stroke.
登录
查看更多内容
组织纤溶酶原激活剂治疗急性缺血性中风的成本效益。
影响因子：
9.9
作者：
J. Riggs;Morgantown;Zurab Nadareishvili;Paul J. Oh;L. Smurawska;Chau T T Tran;J. Norris;S. Fagan
通讯作者：
S. Fagan
影响因子：
8.3
作者：
Tilley, BC;Marler, J;Grotta, J
通讯作者：
Grotta, J
药物经济学研究中的患者自我报告
DOI：
--
发表时间：
1999
期刊：
PharmacoEconomics (Auckland)
影响因子：
--
作者：
C. Evans;B. Crawford
通讯作者：
B. Crawford
影响因子：
2.1
作者：
Finestone, Hillel M.;Guo, Meiqi;Jessup, Anita
通讯作者：
Jessup, Anita
医疗保健利用的调查措施是否具有误导性？
DOI：
10.1071/ah010091
发表时间：
2001
期刊：
Australian health review : a publication of the Australian Hospital Association
影响因子：
--
作者：
R. Marshall;D. Grayson;Anthony F Jorm;B. O'Toole
通讯作者：
B. O'Toole